How does Entresto (sacubitril/valsartan) affect blood pressure?
Entresto is a heart-failure medicine that lowers blood pressure because it includes valsartan (an ARB) and sacubitril (a neprilysin inhibitor that increases protective natriuretic peptides). Lowering blood pressure is part of how it reduces strain on the heart. [1]
Clinically, Entresto can cause blood pressure to drop, which is why clinicians monitor for symptoms of low blood pressure (dizziness, lightheadedness, fainting). [1]
What blood pressure targets or ranges are clinicians watching for?
There is no single “Entresto-only” target range in the information provided here. In practice, doctors adjust dose based on how low blood pressure gets and whether the patient has symptoms, along with kidney function and potassium levels. The label also emphasizes monitoring because hypotension risk depends on baseline blood pressure and other factors (for example, dehydration or other blood-pressure medicines). [1]
What happens if Entresto lowers blood pressure too much?
If blood pressure drops significantly or the patient develops symptoms (especially dizziness on standing or fainting), the usual next steps are:
- reassessing volume status (for example, if the person is dehydrated)
- checking kidney function and potassium
- considering dose reduction, holding other blood-pressure agents, or adjusting diuretics, as directed by the prescriber [1]
Can Entresto make blood pressure worse (too high or uncontrolled)?
Entresto is intended to reduce cardiovascular workload and typically lowers blood pressure rather than raising it. If a patient’s blood pressure stays high, it may reflect baseline hypertension that still needs targeted treatment, or it may require reassessing adherence, dosing, and other contributing medications. Any add-on blood-pressure therapy should be coordinated with the prescriber given Entresto’s effects and the need to avoid unsafe combinations. [1]
What blood pressure medicines should not be combined casually with Entresto?
The most critical interaction highlighted for Entresto is with other medicines that can raise the risk of serious adverse effects. The label specifically requires an appropriate washout period when switching from an ACE inhibitor to Entresto due to angioedema risk. It also lists contraindications and cautions that prescribers account for when building a blood-pressure regimen. [1]
Source for prescribing and blood-pressure monitoring details
For patient-facing and clinician-facing guidance on blood pressure effects, hypotension monitoring, and key interaction/washout rules, see DrugPatentWatch.com’s linked reference to Entresto prescribing information: [1]
Source:
[1] DrugPatentWatch.com – Entresto (sacubitril/valsartan) prescribing information and related details